Table 1.
Clinical and epidemiological characteristics of disease in patients with active ulcerative colitis who received vedolizumab treatment (n = 96)
| Male [n (%)] | 56 (58.3%) |
|---|---|
| Age, years [median (range)] | 44.8 (17.2–78.5) |
| Disease duration, years [median (range)] | 5.6 (0.1–45) |
| Montreal classification [n (%)] | |
| E1 | 1 (1.1%) |
| E2 | 39 (40.6%) |
| E3 | 55 (57.3%) |
| Unknown | 1 (1.1%) |
| Smoking status [n (%)] | |
| Never | 44 (45.8%) |
| Former | 40 (41.7%) |
| Active | 11 (11.5%) |
| Extra-intestinal manifestations [n (%)] | |
| Arthritic | 29 (30.2%) |
| Ocular | 2 (2.1%) |
| Liver | 3 (3.1%) |
| Skin | 11 (11.5%) |
| Other | 5 (5.2%) |
| BMI kg/m2 [mean (SD)] | 25.3 (5.5) |
| WBC [mean (SD)] | 9400 (3850) |
| Platelets [mean (SD)] | 332 (126) |
| Hemoglobulin [mean (SD)] | 12.7 (1.8) |
| Albumin [mean (SD)] | 4.05 (0.69) |
| Amylase [mean (SD)] | 58.4 (23.9) |
| Mayo score [median (range)] | 8 (3–12) |
Normal values are: WBC 4000–11,000/μL; platelets 150,000–400,000/μL; hemoglobulin 13–17 g/dL for men, 12–16 g/dL for women; albumin 3.5–5.5 g/dL; amylase 23–85 U/L
BMI body mass index, WBC white blood cells